A Phase I Study of GA101 (RO5072759) Monotherapy Followed by Maintenance in Patients with Multiply Relapsed/Refractory CD20+ Malignant Disease

MLA

Laurie H. Sehn, et al. “A Phase I Study of GA101 (RO5072759) Monotherapy Followed by Maintenance in Patients with Multiply Relapsed/Refractory CD20+ Malignant Disease.” Blood, vol. 114, Nov. 2009, p. 934. EBSCOhost, https://doi.org/10.1182/blood.v114.22.934.934.

APA

Laurie H. Sehn, Jaimal Kothari, Douglas A. Stewart, Sarit Assouline, Michael Crump, Pavel Pisa, & Joy Mangel. (2009). A Phase I Study of GA101 (RO5072759) Monotherapy Followed by Maintenance in Patients with Multiply Relapsed/Refractory CD20+ Malignant Disease. Blood, 114, 934. https://doi.org/10.1182/blood.v114.22.934.934

Chicago

Laurie H. Sehn, Jaimal Kothari, Douglas A. Stewart, Sarit Assouline, Michael Crump, Pavel Pisa, and Joy Mangel. 2009. “A Phase I Study of GA101 (RO5072759) Monotherapy Followed by Maintenance in Patients with Multiply Relapsed/Refractory CD20+ Malignant Disease.” Blood 114 (November): 934. doi:10.1182/blood.v114.22.934.934.